Navigation Links
Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
Date:5/12/2008

strengthens Intercell's position as an innovative vaccine company and is highly complementary with its proprietary antigen identification and adjuvant vaccine technology platforms (AIP(R) and IC31(R)). TCI adds an important third arm to Intercell's leading vaccine technologies, specifically a delivery platform for antigens and adjuvants that can facilitate the development of a broad range of in-house and partnered vaccine products. Both companies have already partnered technologies with Merck & Co., Inc., the most recent one being Iomai's agreement to conduct proof-of-principle preclinical studies evaluating the use of its needle-free immunostimulant patch. Intercell plans to further leverage the TCI technology by applying it to other vaccines in its development pipeline, such as its Pneumococcus vaccine candidate.

Furthermore, Iomai's vaccine patch has the potential to provide cheaper and more effective medication to those living in endemic areas, in particular high risk groups such as children and the elderly located in developing countries in Africa, Asia and Latin America.

Transaction Terms:

Under the terms of the merger agreement, Intercell will acquire Iomai for USD 6.60 per share of Iomai's common stock representing a fully diluted equity value of Iomai of approximately USD 189 million (EUR 122 million). The consideration will be paid in cash and stock. Iomai's public shareholders, representing approximately 59 percent of Iomai's outstanding common stock will receive cash. Certain of Iomai's largest shareholders, together representing approximately 41 percent of Iomai's outstanding common stock, have agreed to exchange their shares for Intercell stock at an exchange ratio corresponding to a value of USD 6.60 per share of Iomai common stock upon closing.

The combination is structured as a share exchange together with a merger of Iomai and a US subsidiary of Intercell. Certain of Iomai's largest shareholders (and their affiliates), w
'/>"/>

SOURCE Iomai Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
2. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
3. Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.
4. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
5. U.S. Preventive Medicine Acquires Specialty Disease Management
6. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
7. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
8. Nastech Reacquires Teriparatide (Parathyroid Hormone; PTH1-34) Nasal Spray from Procter & Gamble
9. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
10. Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA
11. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... PITTSBURGH , Aug. 4, 2015  The Pittsburgh ... sciences investment firm, announced today that one of its ... to sell their Flex ® Robotic System in ... pleased or more proud of Medrobotics," said John ... have come a very long way since spinning out ...
(Date:8/4/2015)...  Sutro Biopharma today announced that it has ... president of alliance and project management. Dr. Vasquez ... of Sutro,s collaborative partnerships and the development of ... antibodies and antibody-based therapeutics targeting immuno-oncology pathways. ... of experience in the biopharmaceutical sector with expertise ...
(Date:8/4/2015)... Aug. 4, 2015 Research and Markets ... of Jain PharmaBiotech,s new report "Transdermal ... to their offering. ... - an approach used to deliver drugs ... an alternative to oral,intravascular, subcutaneous and transmucosal ...
Breaking Medicine Technology:Pittsburgh Life Sciences Greenhouse Portfolio Client Medrobotics Receives FDA Market Clearance 2Pittsburgh Life Sciences Greenhouse Portfolio Client Medrobotics Receives FDA Market Clearance 3Sutro Biopharma Appoints Nicki Vasquez, Ph.D. as VP of Alliance and Project Management 2Transdermal Drug Delivery Report 2015-2024 - Technologies, Markets, and Companies Analysis 2
... 350+ Targeted Drugs on the Market and, in Clinical Development ... Resistance, Enhance Anticancer Effects, and Expand the Markets for ... ... 19 Identification of novel,cancer-related targets and pathways is redefining our ...
... 19 Compendia Bioscience, Inc.,today announced results of ... commitment from all major customers and the addition ... customer roster. The new,customers and existing customer commitment ... with similar growth forecasted for 2008., (Logo: ...
Cached Medicine Technology:Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics 2Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics 3Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics 4On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments 2On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments 3
(Date:8/4/2015)... Hills, CA (PRWEB) , ... August 04, 2015 ... ... personal consultation complete with full examination now offered by the world renowned ... more beautiful aesthetic facial appearance through cosmetic surgery techniques helps individuals to achieve ...
(Date:8/4/2015)... ... August 04, 2015 , ... Providigm, LLC, ... care facilities, today announced details of the Advanced level of their national accreditation ... Providigm’s QAPI Accreditation program , introduced in 2013, is based on standards ...
(Date:8/4/2015)... D.C. (PRWEB) , ... August ... ... that its HealthCenter personal health record (PHR) product has achieved Office of ... and Inpatient EHR Certification from Drummond Group. HealthCenter delivers the highest quality ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... and Scale-up Online Seminar featuring researchers from Lubrizol, Pfizer, and Merck. ... PM EDT. , Process development project timelines often require informed decisions with limited ...
(Date:8/4/2015)... ... ... The results of a three year clinical trial for the Argus II, ... causes blindness, were published on June 23, 2015 in Ophthalmology , the journal ... implant, more commonly known as the “bionic eye,” is safe and effective for long-term ...
Breaking Medicine News(10 mins):Health News:Beverly Hills Surgeon, Dr. Paul Nassif, is Now Offering Personal Consultations with Full Examinations for Facial Plastic Surgeries 2Health News:Beverly Hills Surgeon, Dr. Paul Nassif, is Now Offering Personal Consultations with Full Examinations for Facial Plastic Surgeries 3Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 2Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 3Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 2Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 3Health News:METTLER TOLEDO Announces New Process Chemistry and Scale-up Online Seminar 2Health News:“Bionic Eye” Implant for the Blind Proved Safe and Effective at the End of a Three Year Clinical Trial 2
... A small study suggests that adults whose parents are ... have lower average levels of the stress hormone cortisol ... to a report in the September issue of Archives ... Biological differences seen in individuals with PTSD, including low ...
... nonprofit patient advocacy group, today released updated resources,to help ... back to,school. The organization offers a free fact sheet ... and deliver to their child,s school,teacher; and it offers ... how to treat psoriasis in children and how to ...
... , , MONDAY, Sept. 3 (HealthDay News) --The more hours adults ... job, the less time they spend sleeping. , That,s the ... on slumber. , Adults who sleep four-and-a-half hours or fewer ... 118 minutes more on weekends than the average sleeper, a ...
... LES ULIS, France, September 3 - QUANTEL ... in View,of Acquiring the Company WaveLight Aesthetic GmbH ... the German company WaveLight AG, is,specialized in Dermatology/Aesthetic lasers. ... its revenues are estimated of approx. 10MEUR,for the fiscal ...
... Cambridge, famous as a haunt of students in their ... next generation of antibiotics, according to scientists speaking today ... Microbiologys 161st Meeting at the University of Edinburgh, UK, ... now over-prescribed for treatments of bacterial infections, and patients ...
... Lexington, KY (Aug. 31, 2007) Two worldwide studies published ... growth rate of chronic obstructive pulmonary disease (COPD). The only ... Study was located in Eastern Kentucky, and was found to ... world. In fact, it had the second highest rate ...
Cached Medicine News:Health News:Adult offspring of parents with PTSD have lower cortisol levels 2Health News:Psoriasis Cure Now offers 'Back to School' Resources for Parents of Children with Psoriasis 2Health News:Work Time Predicts Sleep Time 2Health News:QUANTEL Intends to Strengthen its Dermatology/ Aesthetics Division With the Acquisition of WaveLight Aesthetic GmbH 2Health News:New viruses to treat bacterial diseases -- 'My enemies' enemy is my friend' 2Health News:Two studies published in the Lancet 2
Mid-level interpretive resting ECG...
... The ECG-9010 meets IEC60601-2-51 new international ... and digital filter performance. ECG data ... a Windows PC with the optional ... changed for operating in other countries, ...
The Sonic WAVE™is the first market-ready Alternative to Ultrasound...
... is an innovative, stat analyzer that measures ... on-board co-oximetry and integrated data management "all ... include pH, PCO 2 , PO 2 ... sodium, potassium, chloride, ionized calcium, ionized magnesium, ...
Medicine Products: